Inovio Q1 2023 Earnings Report
Key Takeaways
Inovio reported a net loss of $40.6 million, or $0.16 per share, for the quarter ended March 31, 2023. The company ended the quarter with $223.8 million in cash, cash equivalents and short-term investments and expects its cash runway to extend into the first quarter of 2025.
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients.
Announced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO®.
Announced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions.
Ended the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investments.
Inovio
Inovio
Forward Guidance
INOVIO continues to expect its cash runway to extend into the first quarter of 2025. This projection includes a cash burn estimate of approximately $33 million for the second quarter 2023 and its ongoing expectation that cash burn will decrease incrementally from there into the first quarter of 2025.